Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00584298 |
This study is designed to provide information on feasibility and reproducibility of barostat assessments of colorectal sensory functions and compliance and their pharmacological modulation
Condition | Intervention | Phase |
---|---|---|
Irritable Bowel Syndrome (IBS) |
Drug: SMS995 Drug: Placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment |
Official Title: | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Women With Irritable Bowel Syndrome to Evaluate Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide. |
Enrollment: | 50 |
Study Start Date: | January 2008 |
Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental | Drug: SMS995 |
2: Placebo Comparator | Drug: Placebo |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Understand and sign the written informed consent
Exclusion Criteria:
United States, Massachusetts | |
Novartis Investigator Site | |
Boston, Massachusetts, United States, 02215 | |
United States, Minnesota | |
Novartis Investigator Site | |
Rochester, Minnesota, United States, 55905 | |
Canada | |
Novartis Investigator Site | |
Hamilton, Canada | |
Sweden | |
Novartis Investigator Site | |
Gothenburg, Sweden | |
United Kingdom | |
Novartis Investigator Site | |
Manchester, United Kingdom | |
Novartis Investigator Site | |
Nottingham, United Kingdom | |
Novartis Investigator Site | |
London, United Kingdom |
Principal Investigator: | NOVARTIS | Novartis investigator site |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CSMS995A2101 |
Study First Received: | December 21, 2007 |
Last Updated: | May 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00584298 History of Changes |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada; United Kingdom: Medicines and Healthcare Products Regulatory Agency; Sweden: Medical Products Agency |
Barostat distention IBS irritable bowel |
syndrome colorectal sensation modulation reproducibility |
Digestive System Diseases Antineoplastic Agents, Hormonal Dilatation, Pathologic Gastrointestinal Diseases Colonic Diseases |
Irritable Bowel Syndrome Octreotide Intestinal Diseases Colonic Diseases, Functional |
Disease Antineoplastic Agents, Hormonal Gastrointestinal Diseases Antineoplastic Agents Colonic Diseases Gastrointestinal Agents Octreotide Intestinal Diseases |
Pharmacologic Actions Digestive System Diseases Pathologic Processes Syndrome Therapeutic Uses Irritable Bowel Syndrome Colonic Diseases, Functional |